 Aldeyra Therapeutics, Inc. Nasdaq: ALDX Aldeyra today announced that ADX-2191 has been designated an orphan medicinal product by the European Commission for the treatment of retinal detachment. ADX-2191 is an investigational therapy in clinical development in the U.S. for the prevention of proliferative vitreoretinopathy PVR, a rare but serious sight-threatening retinal disease with no approved treatment. PVR is the leading cause of failure of rhegmatogenous retinal detachment surgery. 